On the contrary, the clinical data suggest that as BDNF Met66 reduces BDNF availability in the CNS, this reduction in neurotrophic factors may allow faster Aβ + related tau hyperphosphorylation, subsequent neurodegeneration and cognitive decline. This evidence concerns the gene MAPT and Mental deterioration.